Skip to content
Entyvio(vedolizumab)
Entyvio (vedolizumab) is an antibody pharmaceutical. Vedolizumab was first approved as Entyvio on 2014-05-20. It is used to treat crohn disease, enteritis, and ulcerative colitis in the USA. It has been approved in Europe to treat crohn disease and ulcerative colitis.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
Trade Name
FDA
EMA
Entyvio
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Vedolizumab
Tradename
Proper name
Company
Number
Date
Products
EntyviovedolizumabTakedaN-125476 RX2014-05-20
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
entyvioBiologic Licensing Application2020-11-12
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
crohn diseaseEFO_0000384D003424K50
enteritisD004751K52.9
ulcerative colitisEFO_0000729D003093K51
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L04: Immunosuppressants
L04A: Immunosuppressants
L04AA: Selective immunosuppressants
L04AA33: Vedolizumab
HCPCS
Code
Description
J3380
Injection, vedolizumab, 1 mg
Clinical
Clinical Trials
97 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ulcerative colitisD003093EFO_0000729K513612121043
Crohn diseaseD003424EFO_0000384K50371112639
Inflammatory bowel diseasesD015212EFO_0003767112610
PsoriasisD011565EFO_0000676L4011
PouchitisD019449EFO_0003921K91.85011
Self efficacyD02037711
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sclerosing cholangitisD015209EFO_0004268K83.0111
Myelodysplastic syndromesD009190D4611
LymphomaD008223C85.911
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.011
Biphenotypic leukemia acuteD015456C95.011
Myelomonocytic leukemia juvenileD054429C93.311
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B20233
Non-small-cell lung carcinomaD002289222
MelanomaD008545212
ColitisD003092EFO_0003872K52.9222
Lung neoplasmsD008175C34.90111
Celiac diseaseD002446EFO_0001060K90.011
Graft vs host diseaseD006086D89.8111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients55
Diet therapyD00403511
HivD006678O98.711
Macular degenerationD008268EFO_0001365H35.3011
Type 1 diabetes mellitusD003922EFO_0001359E1011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
TherapeuticsD01381211
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVEDOLIZUMAB
INNvedolizumab
Description
Vedolizumab (humanized mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID943609-66-3
RxCUI1538097
ChEMBL IDCHEMBL1743087
ChEBI ID
PubChem CID
DrugBankDB09033
UNII ID9RV78Q2002 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Entyvio - Takeda
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,962 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
7,502 adverse events reported
View more details